Overview
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel, cisplatin, and amifostine in treating patients who have advanced non-small cell lung cancer that cannot be surgically removed.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of Wisconsin, MadisonCollaborator:
National Cancer Institute (NCI)Treatments:
Amifostine
Cisplatin
Docetaxel
Criteria
DISEASE CHARACTERISTICS: Histologically proven unresectable advanced non-small cell lungcancer Stable CNS metastases allowed
PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0 or 1 Life expectancy: Not
specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least
2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: AST no greater than 2.5 times upper
limit of normal (ULN) AND alkaline phosphatase no greater than ULN OR AST no greater than
ULN AND alkaline phosphatase no greater than 4 times ULN Renal: Creatinine clearance at
least 60 mL/min Other: Not pregnant Fertile patients must use effective contraception No
peripheral neuropathy worse than grade 1
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Any type and any
number of prior chemotherapy regimens allowed and recovered Greater than 3 months since
prior cisplatin and recovered Endocrine therapy: Prior endocrine therapy allowed and
recovered Radiotherapy: Prior radiotherapy allowed and recovered Surgery: Prior surgery
allowed and recovered Other: No other concurrent medications which could cause renal injury